Abstract Adoptive immunotherapy with chimeric antigen receptor-modified
Introduction

The Rationale for CD19 CAR-T Cell Immunotherapy for B-Cell Malignancies
A component of the adaptive immune system, T cells are effectors of cell-mediated immunity. In response to engagement of the T-cell receptor by a cognate peptide antigen presented in the context of a specific major histocompatibility complex (MHC) molecule, T cells exert effector functions and induce lysis of antigen-bearing target cells. T cells were noted to have anti-tumor effects during studies of T-celldepleted hematopoietic stem cell transplantation (HSCT), in which patients who received grafts depleted of T cells had a higher risk of disease relapse compared to their counterparts who received T-cell replete grafts [1] . Early approaches to generate large numbers of tumor-reactive T cells for adoptive transfer to cancer patients involved repetitive in vitro stimulation with antigen, were cumbersome, and infrequently met with clinical success [2] . More recent efforts have taken advantage of genetic modification strategies to rapidly redirect the specificity of polyclonal T cells by introduction of a tumor-targeted recombinant antigen receptor, such as a chimeric antigen receptor (CAR). A CAR comprises an extracellular antibody-derived single chain variable fragment (scFv) specific for a target antigen that is linked to one or more intracellular T-cell-derived signaling sequences ( Fig. 1) , which enables T-cell activation on ligation of the scFv with its target antigen. Limited therapeutic activity was noted in clinical trials using T cells engineered to express first generation CARs, which contained an intracellular T-cell signaling sequence (e.g., CD3f) in the absence of a costimulatory molecule sequence [3] [4] [5] . Clinical activity has been markedly improved by T-cell products that incorporate second-generation CARs that include co-stimulatory sequences derived, for example, from 4-1BB or CD28 [6] [7] [8] [9] [10] [11] [12] . Third-and fourth-generation CARs, which contain multiple co-stimulatory domains and/or other signals, are in development, but clinical experience with these constructs in B-cell malignancies so far is limited [13, 14] . CD19 is a very good target antigen for CAR-T cell immunotherapy of B-cell malignancies, as it is expressed at high and stable levels on tumor tissue from most patients with B-cell acute lymphoblastic leukemia (B-ALL), nonHodgkin's lymphoma (NHL), and chronic lymphocytic leukemia (CLL). It is also expressed on normal B cells, but not on other tissues outside the B-cell lineage, limiting known ''on-target off-tumor'' toxicities to B-cell aplasia, a condition that can be managed with immunoglobulin replacement [15] .
Lymphodepletion Chemotherapy, CAR-T Cell
Manufacturing, and Infusion
Approaches for CAR-T cell production differ at each center, but typically involve isolation of autologous T cells from the patient using leukapheresis, followed by in vitro stimulation with anti-CD3 or anti-CD3/anti-CD28 beads, genetic modification by transduction with a retroviral or lentiviral vector to express a CAR, and subsequent culture for approximately 2-3 weeks. After leukapheresis and while CAR-T cells are being manufactured, patients in most protocols will receive lymphodepleting chemotherapy, which creates a favorable immune environment for adoptively transferred CAR-T cells, improving their in vivo expansion, subsequent persistence, and clinical activity ( Fig. 2 ) [16] . During the acute phase of in vivo CAR-T cell expansion, patients are monitored closely for the development of adverse effects of CAR-T cell immunotherapy, such as cytokine-release syndrome (CRS) and neurotoxicity. CRS is associated with immune T-cell activation and is characterized by fevers, hypotension, capillary leak, and coagulopathy [17] . Neurotoxicity commonly presents as delirium, but can be manifest as focal neurological deficits, seizures, or coma. Neurotoxicity usually occurs in association with CRS, but its A first-generation CAR incorporates a CD19-specific single chain variable fragment (scFv) fused through linker sequences to CD3f. When introduced into a T cell by genetic modification, the CAR allows redirection of T-cell specificity to CD19. Second-and third-generation CARs incorporate additional co-stimulatory domains pathogenesis is unclear. Although in a majority of cases CRS and neurotoxicity are self-limited, the IL-6-receptor antibody, tocilizumab, and/or corticosteroids have been used to treat serious cases. Toxicity grading and therapy algorithms are still under development [7, [17] [18] [19] .
CD19 CAR-T Cell Clinical Trials in B-Cell Malignancies
A majority of the published clinical experience has come out of four centers, each using a distinct CAR design and manufacturing approaches (Table 1) . Clinical trial data from these centers that have been published or recently presented in abstract form at the annual meetings of the American Society of Clinical Oncology (ASCO) or American Society of Hematology (ASH) are presented in this review.
B-ALL
The group at Memorial Sloan Kettering Cancer Center (MSKCC) initially published their experience with five adult B-ALL patients in 2013, followed by a second manuscript in 2014 [18, 20] . Park et al. updated their data to include a total of 51 patients at ASCO 2016 [21] . Following either cyclophosphamide (Cy) or Cy with fludarabine (Flu) lymphodepletion, 1 9 10 6 to 3 9 10 6 CAR-T cells/kg were infused. On restaging after CAR-T cell infusion, of 50 evaluable patients, 41 (82%) had a morphologic complete remission (CR) ( Table 2) . Thirty-nine patients with morphologic CR were evaluated with marrow flow cytometry and 33 were in minimal residual disease (MRD)-negative CR. Thus, the overall MRD-negative CR rate in evaluated patients was approximately 69%. The authors identified a relationship between toxicity and tumor burden; 13 of 31 patients with morphologic disease ([5% blasts) developed severe CRS requiring mechanical ventilation or vasopressors, compared to only one of 20 with MRD [22, 23] . Neurotoxicity occurred in 15 of 51 patients. Three patients with morphologic disease died after receiving 3 9 10 6 CAR-T cells/kg, leading to a riskadapted therapy, in which patients without morphologic disease receive 3 9 10 6 cells/kg, whereas patients with morphologic disease receive a 1 9 10 6 cell/kg dose. In 2015, Lee et al. from the National Cancer Institute (NCI) reported 21 patients, and updated their B-ALL data at ASH 2015 to a total of 38 patients [9, 24] . Lymphodepletion intensity was adjusted according to tumor burden; patients with C25% blasts in the marrow received a variety of high-intensity regimens, while patients with \25% blasts received a lower intensity combination of Cy and Flu. In the initial cohort of 20 patients it was determined that the maximum tolerated dose was 1 9 10 6 CAR-T cells/kg; therefore, this dose was used in the second cohort of 18 patients. MRD-negative CRs were seen in 20 of 38 patients (53%). In those who achieved an MRD-negative CR, leukemia-free survival was 45.5% at 18 months. Sixteen percent of patients in the first cohort and 5.6% in the second cohort developed grade 4 CRS [17] . Neurotoxicity was not reported.
Another report from the NCI outlined treatment of allogeneic HSCT recipients with CAR-T cells manufactured from the HSCT donor and administered without antecedent lymphodepletion chemotherapy [25, 26] . Four of five patients obtained a CR without evidence of acute graft-versus-host disease.
The University of Pennsylvania (UPenn) and Children's Hospital of Philadelphia (CHOP) reported their initial results in 2013 and 2014, with updates at ASCO 2016 [6, 7, 27] . Fifty-nine children and young adults (B24 years old) were treated with 1-10 9 10 7 total T cells/kg with a CAR transduction efficacy of 2.3-45% following a variety of lymphodepletion regimens. Fifty-five (93%) patients achieved a negative marrow by flow cytometry. Twenty patients relapsed, 13 of them with CD19 negative disease, giving a relapse free survival (RFS) of 55% and overall survival (OS) of 79% at 12 months. CRS (any grade) developed in 88% of patients, with severe CRS occurring in 27% and being more frequent in those with high tumor burden.
At ASCO 2016, Frey et al. reported on the UPenn experience with 27 adults in B-ALL, using fixed doses of 5 9 10 7 versus 5 9 10 8 total CAR-T cells given, as a , the CR rate was 64% (ORR 82%)
[11] single infusion or in split fractions [28] . Of nine patients treated with 5 9 10 7 CAR-T cells administered as a single dose, only three obtained a CR, while of the six patients treated with 5 9 10 8 CAR-T cells as a single dose, three achieved CR and three died of severe CRS. After introduction of a fractionated schedule to administer 5 9 10 8 CAR-T cells, the CR rate was 75% (9 of 12). While 75% of patients developed grade 3-4 CRS, no patients died of acute toxicity.
Relationships between infused CAR-T cell dose and clinical outcomes were difficult to define in early studies of CAR-T cell therapy, potentially a result of variability in the T-cell subset composition of the infused CAR-T cell products, which can affect the potency of a CAR-T cell product [29] . In an effort to manufacture a more uniform CAR-T cell product that could assist in defining relationships between infused CAR-T cell dose and clinical outcomes, we developed an approach at Fred Hutchinson Cancer Research Center (FHCRC) in which patients received CAR-T cells formulated in a defined 1:1 ratio of CD4?:CD8? CAR-T cells. The defined composition product was infused at set dose levels of 2 9 10 5 , 2 9 10 6 or 2 9 10 7 CD19 CAR-T cells/kg following lymphodepletion chemotherapy with Cy-based regimens with or without Flu. We recently published our findings in 30 B-ALL patients in early 2016 [12] . Twenty-seven of 29 evaluable patients (94%) achieved a flow cytometry-negative CR; two of these patients were found to have MRD by molecular testing. Twenty-five of the 30 developed CRS, with seven cases being severe enough to require ICU care. Severe toxicity was encountered in two patients treated at the highest dose level; therefore, no further patients were treated with this dose. Similar to other groups, we identified that the burden of CD19? cells in the marrow prior to therapy was a risk factor for subsequent toxicity, leading to a risk-adapted therapy approach in which patients with [20% marrow involvement received 2 9 10 5 cells/kg while those with B20% received 2 9 10 6 cells/kg. After adoption of this approach, only one of ten patients developed severe CRS requiring ICU care. In the early part of the study, we used Cy-based lymphodepletion without Flu. Although CR rates in this cohort were robust, early relapse was noted in a subset of patients, associated with loss of CAR-T cells in blood due to an anti-CAR-T cell immune response directed at epitopes in the murine scFv. This mechanism may contribute to early loss of CAR-T cells in some patients in trials that use a CAR containing a murine scFv (Table 1) . Addition of Flu to Cy in the lymphodepleting regimen minimized the effect of transgene immunogenicity, improving CAR-T cell expansion, persistence, and clinical outcomes.
B-NHL and CLL
In 2015, the NCI group reported treatment of 11 B-NHL patients and four CLL patients [30] . Nine of the 11 NHL patients had aggressive disease on histology (four with diffuse large B-cell lymphoma (DLBCL), NOS, four with primary mediastinal B-cell NHL, one with Richter's transformation to DLBCL after CLL) and two had indolent disease. Patients received lymphodepletion with high-dose Cy (60-120 mg/kg) followed by 5 days of Flu 25 mg/m 2 , with infusion one day later of 1-5 9 10 6 CAR-T cells/kg. Of the nine patients with aggressive histology, seven were evaluable, with four patients achieving a CR and two achieving a partial response (PR). Three of the four CLL patients achieved a CR. Adverse events included grade C3 hypotension in four of 15 (27%) patients and neurotoxicity in six of 15 (40%) patients. One patient died on day 16 from an unclear etiology.
At ASCO 2016, Kochenderfer et al. reported outcomes in 22 patients given low-dose Cy (300-500 mg/m 2 ) for 3 days, with concurrent Flu 30 mg/m 2 administration as lymphodepletion [31] . Eight of 19 DLBCL patients achieved a CR with an overall response rate (ORR) in DLBCL of 68% (13 of 19 patients). One MCL patient and two FL patients obtained CR.
Brudno et al. reported data from treatment of allogeneic HSCT recipients with CAR-T cells that were manufactured from T cells directly isolated from the HSCT donor and administered without antecedent lymphodepletion chemotherapy in 2015 [25, 26] . Ten B-NHL and five CLL patients were treated, with responses observed in two of ten B-NHL patients and two of five CLL patients.
At ASH 2015, UPenn reported treatment of 24 NHL patients with 3.08 9 10 6 to 8.87 9 10 6 CAR-T cells/kg following a range of lymphodepletion regimens [32] . Eight of 11 patients with follicular lymphoma, seven of 15 patients with DLBCL, and one of two patients with mantle cell NHL responded, with an ORR of 68%. Sixteen of 24 patients developed CRS and three patients developed neurotoxicity.
The UPenn group also reported success in CLL, with an ORR of 57% (four of 14 CR, four of 14 PR) [8] . Results from a subsequent phase II dose optimization study in 35 patients were reported at ASCO 2016 [33] . Patients received a high (5 9 10 8 ) or low (5 9 10 7 ) total CD19 CAR-T cell dose. Stage I of the study demonstrated a higher response rate in the high-dose cohort, leading to expansion of this dose level in the stage II group. Nine of the 17 evaluable patients at the high-dose level responded, with an ORR of 53%. Nineteen of 35 patients (48%) developed CRS, of which 7 were grade 3-4.
At ASCO 2016, Geyer et al. from MSKCC reported on treatment of eight patients with refractory CLL after first-line pentostatin, cyclophosphamide, and rituximab [34] . After Cy 600 mg/m 2 , patients were given 3 9 10 6 , 1 9 10 7 , or 3 9 10 7 CAR-T cells/kg. Two patients obtained a CR, with an ORR of 50% (4 of 8). Despite progressive disease in three patients, two had evidence of a marrow response.
We recently reported treatment of 32 patients with a variety of B-NHL histologic types (11 de novo DLBCL, ten transformed DLBCL, five FL, and four MCL) [11] . Of the 30 evaluable patients, ten (33%) had a CR and nine (30%) a PR, giving an ORR of 63%. Severe CRS requiring ICU care was seen in four of 32 (12.5%) patients, and grade C3 neurotoxicity was noted in nine of 32 (28%) patients. As observed in our studies in B-ALL patients, addition of Flu to Cy-based lymphodepletion improved CAR-T cell expansion, persistence, and clinical outcomes in NHL patients. Patients treated at the highest CAR-T cell dose (2 9 10 7 cells/kg) after Cy and Flu lymphodepletion experienced more toxicity; therefore, 2 9 10 6 cells/kg was deemed the maximum tolerated dose. Infusion of this dose after Cy and Flu lymphodepletion to 11 patients resulted in a CR rate of 64% and an ORR of 82%.
At ASCO 2016, we reported 13 CLL patients who were treated with lymphodepletion chemotherapy and CD19 CAR-T cells at FHCRC [35] . All patients had previously received ibrutinib. Of the 12 restaged patients, ten (83%) achieved clearance of the marrow by flow cytometry and six (50%) achieved CR by CT?/-PET imaging.
Challenges in CD19 CAR-T Cell Immunotherapy
Outcomes in relapsed/refractory patients with B-cell malignancies are promising, but many challenges remain.
Toxicities and Management
CRS arises from the activation of CAR-T cells, leading to inflammatory cytokine release, and is manifest as a spectrum of findings, including fever, constitutional symptoms, hypotension, capillary leak, coagulopathy, and organ dysfunction, usually presenting in the first 1-2 weeks after CAR-T cell infusion. Neurotoxicity can occur with or after the onset of CRS, and in some cases can present after resolution of CRS. The pathogenesis is poorly understood. Presentations include delirium, speech disturbances, focal neurological deficits, seizures, and occasionally coma. Both CRS and neurotoxicity are reversible in the majority of cases; however, fatalities may occur. Although tocilizumab and corticosteroids are used to treat severe CRS and neurotoxicity, the roles of these drugs in treatment of neurotoxicity and prophylaxis of CRS or neurotoxicity are unclear. Early detection testing may be able to identify patients at risk of severe toxicity who might benefit from early intervention [11, 12] . Grading systems for CRS and neurotoxicity have been proposed, but none is currently universally accepted [8, 17, 18] .
Failure of CAR-T Cell Immunotherapy
The success of CAR-T cell therapy is associated with the capacity of infused CAR-T cells to proliferate and induce effector function on encounter with antigen-expressing tumor. In most cases, CAR-T cell therapy is delivered as an autologous, patient-specific product, and the outcomes are in part dependent on the quality of the collected T cells and the manufactured product. Approaches to T-cell collection and CAR-T cell manufacturing methods are actively being investigated by many groups in an effort to allow delivery of more consistent and potent products [36] [37] [38] . Even after manufacturing of CAR-T cells with robust in vitro functional capacity, CAR-T cell activation in vivo may be inhibited by a suppressive tumor microenvironment established by the expression of inhibitory molecules and receptors (e.g., PD-1/PD-L1) by the tumor or stromal cells. Combination therapies to limit immune suppression and allow unrestrained activation of CAR-T cells in the tumor microenvironment are in development [39, 40] . Despite good in vivo CAR-T cell expansion and achievement of CR, relapses can occur after CD19 CAR-T cell immunotherapy. Two categories of relapse can be identified. Relapse of tumor that remains CD19-positive can occur due to a suppressive tumor microenvironment, but can also occur in association with loss of CAR-T cell persistence. The reasons for loss of CAR-T cell persistence are complex and may be difficult to determine in individual patients. In a subset of patients an immune response to the CAR transgene can lead to CAR-T cell rejection and loss of persistence. Modification of lymphodepletion regimens to suppress an anti-CAR immune response or use of less immunogenic CAR designs might minimize the impact of immune-mediated CAR-T cell rejection. In other patients, activation-induced cell death (AICD) or senescence may contribute to loss of CAR-T cells. In these situations, strategies to optimize CAR signaling to minimize AICD or improve manufacturing to produce less differentiated CAR-T cells might improve outcomes. Relapse of CD19-negative tumor is a distinct category that involves a change in tumor phenotype to escape an active CD19-directed antitumor immune response, and may occur despite robust CAR-T cell persistence. It appears to be more common in ALL than NHL or CLL. A variety of mechanisms of CD19 loss in tumors have been described, including phenotypic lineage switch and alternative splicing [6, 41, 42] . Targeting additional tumor antigens in combination with CD19 (e.g., CD20 or CD22) is being investigated as a strategy to reduce the risk of CD19-negative escape [43, 44] .
Role of HSCT after CAR-T Cell Therapy
Despite the potential for durable responses in response to CD19 CAR-T cell immunotherapy, it is unclear currently whether additional consolidation approaches such as allogeneic HSCT should be used to maintain remission for a subset of patients who might be at increased risk of relapse. A personalized approach is currently warranted, with more definitive guidelines to be determined by future studies.
Conclusions
CAR-T cell therapy is an effective novel therapeutic with outstanding success in B-ALL and promising results in B-NHL and CLL, signaling a new era of cancer treatment. Understanding CAR-T cell immunotherapy for B-cell malignancies will assist in broadening the field to provide more effective therapies for other malignancies.
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